Federal Register / Vol. 83, No. 125 / Thursday, June 28, 2018 / Notices 30447 

required to respond to a collection of 

information unless it displays a 

currently valid OMB control number. 

DATES: Additional comments may be 

submitted on or before July 30, 2018. 

ADDRESSES: Submit your comments, 

referencing Docket ID Number EPA– 

HQ–OARM–2018–0028, to (1) EPA 

online using www.regulations.gov (our 

preferred method), oei.docket@epa.gov, 

or by mail to: EPA Docket Center, 

Environmental Protection Agency, Mail 

Code 28221T, 1200 Pennsylvania Ave. 

NW, Washington, DC 20460, and (2) 

OMB via email to oira_submission@

omb.eop.gov. Address comments to 

OMB Desk Officer for EPA. 

EPA’s policy is that all comments 

received will be included in the public 

docket without change including any 

personal information provided, unless 

the comment includes profanity, threats, 

information claimed to be Confidential 

Business Information (CBI) or other 

information whose disclosure is 

restricted by statute. 

FOR FURTHER INFORMATION CONTACT: 

Pamela Leftrict, Policy, Training, and 

Oversight Division, Acquisition Policy 

and Training Service Center (3802R), 

Environmental Protection Agency, 1200 

Pennsylvania Ave. NW, Washington, DC 

20460; telephone number: 202–564– 

9463; email address: leftrict.pamela@

epa.gov. 

SUPPLEMENTARY INFORMATION: 

Supporting documents, which explain 

in detail the information that the EPA 

will be collecting, are available in the 

public docket for this ICR. The docket 

can be viewed online at 

www.regulations.gov or in person at the 

EPA Docket Center, WJC West, Room 

3334, 1301 Constitution Ave. NW, 

Washington, DC. The telephone number 

for the Docket Center is 202–566–1744. 

For additional information about EPA’s 

public docket, visit http://www.epa.gov/ 

dockets. 

Abstract: EPA contractors are required 

to disclose business relationships and 

corporate affiliations to determine 

whether EPA’s interests are jeopardized 

by such relationships. Because EPA has 

the dual responsibility of cleanup and 

enforcement and because its contractors 

are often involved in both activities, it 

is imperative that contractors are free 

from conflicts of interest so as not to 

prejudice response and enforcement 

actions. Contractors are required to 

maintain a database of business 

relationships and report information to 

EPA on either an annual basis or when 

each work order is issued. 

Form numbers: None. 

Respondents/affected entities: 

Businesses or organizations performing 

contracts for the EPA. 

Respondent’s obligation to respond: 

Required to obtain or retain benefits. 

Estimated number of respondents: 45. 

Frequency of response: Annually and 

on occasion. 

Total estimated burden: 56,055 hours 

(per year). Burden is defined at 5 CFR 

1320.03(b). 

Total estimated cost: $4,139,627 (per 

year), which includes $0 annualized 

capital or operation & maintenance 

costs. 

Changes in estimates: There is a 

significant reduction in expected 

respondents (135 to 45), burden hours 

(164,525 to 50,055), and costs associated 

with this proposed renewal package 

compared to the ICR currently approved 

by OMB. These reductions are solely a 

result of corrections to the ICR’s burden 

calculations; they are not a product of 

modifications to the collection 

methodology or the actual respondent 

universe. 

Courtney Kerwin, 

Director, Regulatory Support Division. 

[FR Doc. 2018–13921 Filed 6–27–18; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisitions of Shares of a Bank or 

Bank Holding Company 

The notificants listed below have 

applied under the Change in Bank 

Control Act (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire shares of a bank 

or bank holding company. The factors 

that are considered in acting on the 

notices are set forth in paragraph 7 of 

the Act (12 U.S.C. 1817(j)(7)). 

The notices are available for 

immediate inspection at the Federal 

Reserve Bank indicated. The notices 

also will be available for inspection at 

the offices of the Board of Governors. 

Interested persons may express their 

views in writing to the Reserve Bank 

indicated for that notice or to the offices 

of the Board of Governors. Comments 

must be received not later than July 13, 

2018. 

A. Federal Reserve Bank of Atlanta 

(Kathryn Haney, Director of 

Applications) 1000 Peachtree Street NE, 

Atlanta, Georgia 30309. Comments can 

also be sent electronically to 

Applications.Comments@atl.frb.org: 

1. Robert Ward Mullins II, Huntsville, 

Alabama, and Holly S. Mullins, 

Vinemont, Alabama; to become 

members of the previously approved 

Mullins Family Control Group which 

controls FCB Bancshares, Inc., Cullman, 

Alabama, and thereby indirectly 

controls Premier Bank of the South, 

Good Hope, Alabama. 

Board of Governors of the Federal Reserve 

System, June 25, 2018. 

Ann Misback, 

Secretary of the Board. 

[FR Doc. 2018–13914 Filed 6–27–18; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2018–N–0074] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; State Enforcement 

Notifications 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Fax written comments on the 

collection of information by July 30, 

2018. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, Fax: 202– 

395–7285, or emailed to oira_

submission@omb.eop.gov. All 

comments should be identified with the 

OMB control number 0910–0275. Also 

include the FDA docket number found 

in brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: 

JonnaLynn Capezzuto, Office of 

Operations, Food and Drug 

Administration, Three White Flint 

North, 10A–12M, 11601 Landsdown St., 

North Bethesda, MD 20852, 301–796– 

3794, PRAStaff@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 


amozie on DSK3GDR082PROD with NOTICES1
30448 Federal Register / Vol. 83, No. 125 / Thursday, June 28, 2018 / Notices 

State Enforcement Notifications 

OMB Control Number 0910–0275— 

Extension 

This information collection supports 

Agency regulations. Specifically, section 

310(b) of the Federal Food, Drug, and 

Cosmetic Act (FD&C Act) (21 U.S.C. 

337(b)) authorizes a State to enforce 

certain sections of the FD&C Act in its 

own name and within its own 

jurisdiction. However, before doing so, 

a State must provide notice to FDA 

according to § 100.2 (21 CFR 100.2). The 

information required in a letter of 

notification under § 100.2(d) enables us 

to identify the food against which a 

State intends to take action and to 

advise that State whether Federal 

enforcement action against the food has 

been taken or is in process. With certain 

narrow exceptions, Federal enforcement 

action precludes State action under the 

FD&C Act. 

In the Federal Register of February 7, 

2018 (83 FR 5438), FDA published a 60- 

day notice requesting public comment 

on the proposed collection of 

information. FDA received one 

comment in support of the information 

collection. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

21 CFR part Number of 

respondents 

Number of 

responses per 

respondents 

Total annual 

responses 

Average 

burden per 

response 

Total hours 

21 CFR Section 100.2(d) ..................................................... 1 1 1 10 10 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

The estimated burden for this 

information collection has not changed 

since the last OMB approval. The 

estimated reporting burden for 

§ 100.2(d) is minimal because 

enforcement notifications are seldom 

used by States. During the last 3 years, 

we have not received any new 

enforcement notifications; therefore, we 

estimate that one or fewer notifications 

will be submitted annually. Although 

we have not received any new 

enforcement notifications in the last 3 

years, we believe these information 

collection provisions should be 

extended to provide for the potential 

future need of a State government to 

submit enforcement notifications 

informing us when it intends to take 

enforcement action under the FD&C Act 

against a particular food located in the 

State. 

Dated: June 21, 2018. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2018–13868 Filed 6–27–18; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Developmental Therapeutics. 

Date: July 9, 2018. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Sharon K. Gubanich, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6195D, 

MSC 7804, Bethesda, MD 20892, (301) 408– 

9512, gubanics@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: June 22, 2018. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–13894 Filed 6–27–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development of an 

Anti-Mesothelin Chimeric Antigen 

Receptor (CAR) for the Treatment of 

Human Cancer 

AGENCY: National Institutes of Health, 

Department of Health and Human 

Services. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

U.S. Patents and Patent Applications 

listed in the Supplementary Information 

section of this notice to Atara 

Biotherapeutics Inc. (‘‘Atara’’) located in 

South San Francisco, CA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before July 13, 2018 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Rose M. Freel, Ph.D., 

Licensing and Patenting Manager, NCI 

Technology Transfer Center, 8490 

Progress Drive, Suite 400, Frederick, MD 

21701; Telephone: (301)–624–8775; 

Facsimile: (240)–276–5504; Email: 

rose.freel@nih.gov. 

SUPPLEMENTARY INFORMATION: 


amozie on DSK3GDR082PROD with NOTICES1